Evidence map›Paper›PMID 37294891›Full record

ArticleMolecular pharmaceutics2023

The Potency of Cowpea Mosaic Virus Particles for Cancer In Situ Vaccination Is Unaffected by the Specific Encapsidated Viral RNA.

Eunkyeong Jung, Young Hun Chung, Chenkai Mao, Steven N Fiering, Nicole F Steinmetz

Open access · greenAbstract read
In one paragraph

Article in Molecular pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals.Bioengineering (Basel, Switzerland) · 2024
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Eunkyeong JungDepartment of Nanoengineering, University of California San Diego, La Jolla, California 92093, United States.
Young Hun ChungDepartment of Bioengineering, University of California San Diego, La Jolla, California 92093, United States.ORCID 0000-0002-6578-8076
Chenkai MaoDepartment of Microbiology and Immunology, Dartmouth Geisel School of Medicine, Hanover, New Hampshire 03755, United States.
Steven N FieringDepartment of Microbiology and Immunology, Dartmouth Geisel School of Medicine, Hanover, New Hampshire 03755, United States.
Nicole F SteinmetzDepartment of Nanoengineering, University of California San Diego, La Jolla, California 92093, United States.ORCID 0000-0002-0130-0481
University of California San Diego · USDartmouth College · US

Funding

Dual-pronged nano-drug delivery using plant virus-like particles.R01CA224605 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Nicole Franziska Steinmetz · 2017 to 2026
$4.0M
Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian CancerR01CA253615 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, SHAOCHEN, FIERING, STEVEN · 2020 to 2024
$3.1M
Toward translation of a plant virus-based in situ vaccination nanotechnologyR01CA274640 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIERING, STEVEN, RANJAN, ASHISH · 2022 to 2025
$2.5M
NCI NIH HHS R01 CA224605NCI NIH HHS R01 CA253615NCI NIH HHS R01 CA274640
6 · The paper itself

Abstract

Plant virus nanoparticles can be used as drug carriers, imaging reagents, vaccine carriers, and immune adjuvants in the formulation of intratumoral in situ cancer vaccines. One example is the cowpea mosaic virus (CPMV), a nonenveloped virus with a bipartite positive-strand RNA genome with each RNA packaged separately into identical protein capsids. Based on differences in their densities, the components carrying RNA-1 (6 kb) denoted as the bottom (B) component or carrying RNA-2 (3.5 kb) denoted as the middle (M) component can be separated from each other and from a top (T) component, which is devoid of any RNA. Previous preclinical mouse studies and canine cancer trials used mixed populations of CPMV (containing B, M, and T components), so it is unclear whether the particle types differ in their efficacies. It is known that the CPMV RNA genome contributes to immunostimulation by activation of TLR7. To determine whether the two RNA genomes that have different sizes and unrelated sequences cause different immune stimulation, we compared the therapeutic efficacies of B and M components and unfractionated CPMV in vitro and in mouse cancer models. We found that separated B and M particles behaved similarly to the mixed CPMV, activating innate immune cells to induce the secretion of pro-inflammatory cytokines such as IFNα, IFNγ, IL-6, and IL-12, while inhibiting immunosuppressive cytokines such as TGF-β and IL-10. In murine models of melanoma and colon cancer, the mixed and separated CPMV particles all significantly reduced tumor growth and prolonged survival with no significant difference. This shows that the specific RNA genomes similarly stimulate the immune system even though B particles have 40% more RNA than M particles; each CPMV particle type can be used as an effective adjuvant against cancer with the same efficacy as native mixed CPMV. From a translational point of view, the use of either B or M component vs the mixed CPMV formulation offers the advantage that separated B or M alone is noninfectious toward plants and thus provides agronomic safety.

Indexed as

Cancer VaccinesComovirusMelanomaAnimalsCytokinesDisease Models, AnimalDogsMiceRNA, ViralVaccinationCancer VaccinesCytokinesRNA, Viralcancer immunotherapycowpea mosaic virusgenomic RNA-1genomic RNA-2in situ vaccineintratumoral immunotherapy

Identifiers

PMID37294891
PMCPMC10530639
OpenAlexW4379980535

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.